1.The Immune System in Irritable Bowel Syndrome.
Giovanni BARBARA ; Cesare CREMON ; Giovanni CARINI ; Lara BELLACOSA ; Lisa ZECCHI ; Roberto DE GIORGIO ; Roberto CORINALDESI ; Vincenzo STANGHELLINI
Journal of Neurogastroenterology and Motility 2011;17(4):349-359
The potential relevance of systemic and gastrointestinal immune activation in the pathophysiology and symptom generation in the irritable bowel syndrome (IBS) is supported by a number of observations. Infectious gastroenteritis is the strongest risk factor for the development of IBS and increased rates of IBS-like symptoms have been detected in patients with inflammatory bowel disease in remission or in celiac disease patients on a gluten free diet. The number of T cells and mast cells in the small and large intestine of patients with IBS is increased in a large proportion of patients with IBS over healthy controls. Mediators released by immune cells and likely from other non-immune competent cells impact on the function of enteric and sensory afferent nerves as well as on epithelial tight junctions controlling mucosal barrier of recipient animals, isolated human gut tissues or cell culture systems. Antibodies against microbiota antigens (bacterial flagellin), and increased levels of cytokines have been detected systemically in the peripheral blood advocating the existence of abnormal host-microbial interactions and systemic immune responses. Nonetheless, there is wide overlap of data obtained in healthy controls; in addition, the subsets of patients showing immune activation have yet to be clearly identified. Gender, age, geographic differences, genetic predisposition, diet and differences in the intestinal microbiota likely play a role and further research has to be done to clarify their relevance as potential mechanisms in the described immune system dysregulation. Immune activation has stimulated interest for the potential identification of biomarkers useful for clinical and research purposes and the development of novel therapeutic approaches.
Abdominal Pain
;
Animals
;
Antibodies
;
Biomarkers
;
Celiac Disease
;
Cell Culture Techniques
;
Cytokines
;
Diet
;
Diet, Gluten-Free
;
Gastroenteritis
;
Genetic Predisposition to Disease
;
Humans
;
Immune System
;
Inflammatory Bowel Diseases
;
Intestine, Large
;
Irritable Bowel Syndrome
;
Mast Cells
;
Metagenome
;
Risk Factors
;
T-Lymphocytes
;
Tight Junctions
2.Pyridostigmine in Pediatric Intestinal Pseudo-obstruction: Case Report of a 2-year Old Girl and Literature Review
Giovanni DI NARDO ; Federica VISCOGLIOSI ; Francesco ESPOSITO ; Vincenzo STANGHELLINI ; Maria Pia VILLA ; Pasquale PARISI ; Alessia MORLANDO ; Girolamo CALÒ ; Roberto DE GIORGIO
Journal of Neurogastroenterology and Motility 2019;25(4):508-514
Pediatric chronic intestinal pseudo-obstruction is a rare disorder characterized by a severe impairment of gastrointestinal motility leading to intestinal obstruction symptoms in the absence of mechanical causes. The diagnosis is usually clinical and diagnostic work is usually aimed to rule out mechanical obstruction and to identify any underlying diseases. Treatment is challenging and requires a multidisciplinary effort. In this manuscript we describe the youngest child successfully treated with the orally administrable, long-acting, reversible anti-cholinesterase drug, pyridostigmine. Like other drugs belonging to cholinesterase inhibitors, pyridostigmine enhances gut motility by increasing acetylcholine availability in the enteric nervous system and neuro-muscular junctions. Based on the direct evidence from the reported case, we reviewed the current literature on the use of pyridostigmine in severe pediatric dysmotility focusing on intestinal pseudo-obstruction. The overall data emerged from the few published studies suggest that pyridostigmine is an effective and usually well tolerated therapeutic options for patients with intestinal pseudo-obstruction. More specifically, the main results obtained by pyridostigmine included marked reduction of abdominal distension, reduced need of parenteral nutrition, and improvement of oral feeding. The present case and review on pyridostigmine pave the way for eagerly awaited future randomized controlled studies testing the efficacy of cholinesterase inhibitors in pediatric severe gut dysmotility.
Acetylcholine
;
Child
;
Cholinesterase Inhibitors
;
Diagnosis
;
Enteric Nervous System
;
Female
;
Gastrointestinal Motility
;
Humans
;
Intestinal Obstruction
;
Intestinal Pseudo-Obstruction
;
Parenteral Nutrition
;
Pyridostigmine Bromide